IP Library Granted Patent US 6,893,840
Granted Patent B2
US 6,893,840 · App. 09/977,066 · Granted May 17, 2005

Cytomegalovirus Intron A fragments

Assignee: Chiron Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,893,840
App. No.
09/977,066
Granted
May 17, 2005
Kind
B2
Abstract

Cytomegalovirus (CMV) Intron A fragments for expressing gene products are disclosed. Also described are expression vectors including the fragments, as well as methods of using the same.

Claims (26)

1. A human cytomegalovirus (hCMV) Intron A fragment, wherein said fragment has an internal deletion of at least 10 nucleotides of the full-length Intron A sequence and comprises: (a) the contiguous sequence of nucleotides found at positions 1-25 of SEQ ID NO: 1, and (b) the contiguous sequence of nucleotides found at positions 775-820 of SEQ ID NO: 1, wherein when said fragment is present in an expression construct, the expression construct directs the transcription of a coding sequence present in the construct at levels equal to, or greater than, those levels achieved by an expression construct that includes a corresponding intact, full-length Intron A sequence.

2. The Intron A fragment of claim 1 , wherein when said fragment is present in an expression construct, the expression construct directs the transcription of a coding sequence present in the construct at levels at least two-fold greater than those levels achieved by an expression construct that includes a corresponding intact, full-length Intron A sequence.

3. A recombinant expression construct effective in directing the transcription of a selected coding sequence, said expression construct comprising:

(a) a coding sequence;

(b) control elements that are operably linked to said coding sequence, wherein said control elements comprise the Intron A fragment of claim 1 ,

whereby said coding sequence can be transcribed and translated in a host cell.

4. A host cell comprising the recombinant expression construct of claim 3 .

5. The recombinant expression construct of claim 3 , wherein said control elements further comprise a promoter selected from the group consisting of a simian virus 40 (SV40) early promoter, a cytomegalovirus (CMV) promoter, a mouse mammary tumor virus long terminal repeat promoter, an adenovirus major late promoter, a rous sarcoma virus (RSV) promoter, a SRα promoter, and a herpes simplex virus promoter.

6. The Intron A fragment of claim 1 , wherein said fragment comprises: the contiguous sequence of nucleotides found at positions 1-51 of SEQ ID NO:1, and (b) the contiguous sequence of nucleotides found at positions 741-820 of SEQ ID NO:1, wherein when said fragment is present in an expression construct, the expression construct directs the transcription of a coding sequence present in the construct at levels equal to, or greater than those levels achieved by an expression construct that includes a corresponding intact, full-length Intron A sequence.

7. The Intron A fragment of claim 6 , wherein when said fragment is present in an expression construct, the expression construct directs the transcription of a coding sequence present in the construct at levels at least two-fold greater than those levels achieved by an expression construct that includes a corresponding intact, full-length Intron A sequence.

8. The Intron A fragment of claim 6 , wherein said fragment comprises in 5′ to 3′ order: the sequence of nucleotides 1-51 of SEQ ID NO:1, linked to nucleotides 741-820 of SEQ ID NO:1.

9. A recombinant expression construct effective in directing the transcription of a selected coding sequence, said expression construct comprising:

(a) a coding sequence;

(b) control elements that are operably linked to said coding sequence, wherein said control elements comprise the Intron A fragment of claim 8 ,

whereby said coding sequence can be transcribed and translated in a host cell.

10. A host cell comprising the recombinant expression construct of claim 9 .

11. A human cytomegalovirus (hCMV) Intron A fragment, wherein said fragment comprises the nucleotide sequence of SEQ ID NO:3, or a nucleotide sequence with at least 95% sequence identity thereto, wherein when said fragment is present in an expression construct, the expression construct directs the transcription of a coding sequence present in the construct at levels equal to, or greater than, those levels achieved by an expression construct that includes a corresponding intact, full-length Intron A sequence.

12. The Intron A fragment of claim 11 , wherein said fragment consists of the nucleotide sequence of SEQ ID NO:3.

13. A recombinant expression construct effective in directing the transcription of a selected coding sequence, said expression construct comprising:

(a) a coding sequence;

(b) control elements that are operably linked to said coding sequence, wherein said control elements comprise the Intron A fragment of claim 12 ,

whereby said coding sequence can be transcribed and translated in a host cell.

14. A host cell comprising the recombinant expression construct of claim 13 .

15. The recombinant expression construct of claim 13 , wherein said control elements further comprise the hCMV immediate-early (IE1) enhancer/promoter region found at nucleotide positions 460 to 1264 of SEQ ID NO:4, and said control elements further comprise the sequence of nucleotides at positions 821-834 of SEQ ID NO:1.

16. A host cell comprising the recombinant expression construct of claim 15 .

17. A human cytomegalovirus (hCMV) Intron A fragment, wherein said fragment comprises in 5′ to 3′ order: a sequence of nucleotides having at least 95% sequence identity to the contiguous sequence of nucleotides found at positions 1-51 of SEQ ID NO:1 linked to a sequence of nucleotides having at least 95% sequence identity to the contiguous sequence of nucleotides found at positions 741-820 of SEQ ID NO: 1, wherein when said fragment is present in an expression construct, the expression construct directs the transcription of a coding sequence present in the construct at levels equal to, or greater than, those levels achieved by an expression construct that includes a corresponding intact, full-length Intron A sequence.

Assignments (2)
MERGER Recorded Oct 21, 2010
From: CHIRON CORPORATION
To: NOVARTIS VACCINES & DIAGNOSTICS, INC.
Reel/Frame 025174/0942 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2005
From: THUDIUM, KENT; SELBY, MARK
To: CHIRON CORPORATION
Reel/Frame 016252/0905 →
Continuity (2)
Provisional Application 6024050200 · Oct 13, 2000
Related Publication 20050079488A1 · Apr 14, 2005